<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Congenital cytomegalovirus infection: Management and outcome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Congenital cytomegalovirus infection: Management and outcome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Congenital cytomegalovirus infection: Management and outcome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gail J Demmler-Harrison, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H22557885"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Congenital cytomegalovirus (CMV) infection is the leading cause of nonhereditary sensorineural hearing loss and can cause other long-term neurodevelopmental disabilities, including cerebral palsy, intellectual disability, vision impairment, and seizures. Infants congenitally infected with CMV may benefit from antiviral therapy, especially if treatment is initiated within the first month of life.</p><p>The management and outcome of congenital CMV infection are reviewed below. The clinical features and diagnosis of congenital CMV infection, other TORCH infections, CMV in pregnancy, and CMV infections in older infants and children are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14430.html" rel="external">"Congenital cytomegalovirus infection: Clinical features and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6011.html" rel="external">"Overview of TORCH infections"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4810.html" rel="external">"Cytomegalovirus infection in pregnancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5965.html" rel="external">"Overview of cytomegalovirus infections in children"</a>.)</p><p></p><p class="headingAnchor" id="H18753549"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>Infants with congenital CMV infection are classified according to the presence or absence of apparent symptoms at the time of birth.</p><p class="bulletIndent1"><span class="glyph">●</span>The term "<strong>symptomatic</strong>" refers to infants with one or more symptoms at birth. Infants with symptomatic congenital CMV infection may have mild, moderate, or severe manifestations. (See  <a class="medical medical_review" href="/d/html/14430.html" rel="external">"Congenital cytomegalovirus infection: Clinical features and diagnosis", section on 'Symptomatic neonate'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We use the term "<strong>primary neurophenotype</strong>" to refer to patients with only central nervous system manifestations. This is a newly described category of symptomatic infants, and the use of this term in the published literature is inconsistent. Infants in this category may appear completely healthy at birth or may have mild microcephaly. They usually are not diagnosed with congenital CMV infection at birth unless they are cared for at a center where all newborns are screened for CMV. As they grow, they develop more significant microcephaly and neurologic manifestations (eg, global developmental delay, abnormal tone, seizures). If neuroimaging is performed, it typically shows polymicrogyria or other cortical dysplasia. (See  <a class="medical medical_review" href="/d/html/14430.html" rel="external">"Congenital cytomegalovirus infection: Clinical features and diagnosis", section on 'Neuroimaging'</a> and  <a class="medical medical_review" href="/d/html/14430.html" rel="external">"Congenital cytomegalovirus infection: Clinical features and diagnosis", section on 'Primary neurophenotype'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The term "<strong>asymptomatic</strong>" refers to infants with no apparent symptoms at birth, although some of these infants may develop hearing loss or subtle symptoms later in life.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The term "<strong>asymptomatic with isolated hearing loss</strong>" refers to infants with isolated hearing loss at birth but no other symptoms. In studies of congenital CMV infection after the advent of universal newborn hearing screening, categorization of these infants as "symptomatic" or "asymptomatic" is inconsistent. Historically, they were often classified as "asymptomatic" because the hearing loss may not have been detected at birth. However, with universal newborn hearing screening, many such infants come to medical attention in the newborn period. We consider these infants to represent a distinct category because they are not truly asymptomatic, but their disease is generally milder than that of symptomatic infants.</p><p></p><p class="headingAnchor" id="H22557899"><span class="h1">SUPPORTIVE MEASURES</span><span class="headingEndMark"> — </span>A small subset of neonates with symptomatic congenital CMV infection have severe, life-threatening presentation (eg, sepsis-like illness, myocarditis, viral-induced hemophagocytic lymphohistiocytosis, or severe neurologic involvement). (See  <a class="medical medical_review" href="/d/html/14430.html" rel="external">"Congenital cytomegalovirus infection: Clinical features and diagnosis", section on 'Life-threatening disease'</a>.)</p><p>Supportive measures for the symptomatic neonate with severe or life-threatening disease may include:</p><p class="bulletIndent1"><span class="glyph">●</span>Fluid maintenance (see  <a class="medical medical_review" href="/d/html/5065.html" rel="external">"Fluid and electrolyte therapy in newborns"</a> and  <a class="medical medical_review" href="/d/html/6122.html" rel="external">"Maintenance intravenous fluid therapy in children"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transfusion of platelets and other blood products (see  <a class="medical medical_review" href="/d/html/5041.html" rel="external">"Red blood cell (RBC) transfusions in the neonate"</a> and  <a class="medical medical_review" href="/d/html/97752.html" rel="external">"Neonatal thrombocytopenia: Clinical manifestations, evaluation, and management", section on 'Platelet transfusion'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Control of seizures (see  <a class="medical medical_review" href="/d/html/6201.html" rel="external">"Treatment of neonatal seizures"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Provision of oxygen and mechanical ventilator support (see  <a class="medical medical_review" href="/d/html/5032.html" rel="external">"Overview of mechanical ventilation in neonates"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nutritional support (see  <a class="medical medical_review" href="/d/html/15634.html" rel="external">"Parenteral nutrition in infants and children"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antimicrobial treatment for secondary bacterial infections (see  <a class="medical medical_review" href="/d/html/5046.html" rel="external">"Management and outcome of sepsis in term and late preterm neonates"</a> and  <a class="medical medical_review" href="/d/html/89456.html" rel="external">"Treatment and prevention of bacterial sepsis in preterm infants &lt;34 weeks gestation"</a>)</p><p></p><p class="headingAnchor" id="H22557906"><span class="h1">ANTIVIRAL TREATMENT</span><span class="headingEndMark"> — </span>Intravenous (IV) <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> and its orally available prodrug, <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a>, are the first-line antiviral agents of choice for treatment of congenital CMV disease. These medications have been evaluated in multicenter, randomized clinical trials in newborns with symptomatic congenital CMV infection and have demonstrated a benefit when treatment is initiated within the first month of life [<a href="#rid1">1-3</a>]. The antivirals <a class="drug drug_pediatric" data-topicid="13325" href="/d/drug information/13325.html" rel="external">foscarnet</a> and <a class="drug drug_pediatric" data-topicid="13155" href="/d/drug information/13155.html" rel="external">cidofovir</a> are reserved for cases of refractory CMV disease, ganciclovir resistance, ganciclovir toxicity, and coinfection with adenovirus. (See <a class="local">'Alternative antiviral agents'</a> below.)</p><p class="headingAnchor" id="H133921"><span class="h2">Who to treat</span></p><p class="headingAnchor" id="H155659594"><span class="h3">Antenatal treatment</span><span class="headingEndMark"> — </span>Maternal antiviral therapy for preventing vertical transmission is challenging since most maternal infections are asymptomatic and screening for CMV is not routinely performed during pregnancy in most settings. However, for pregnant individuals who are identified as having primary CMV infection in early pregnancy, antiviral therapy is suggested. This issue is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4810.html" rel="external">"Cytomegalovirus infection in pregnancy", section on 'Maternal treatment for fetal benefit'</a>.)</p><p class="headingAnchor" id="H4281193211"><span class="h3">Postnatal treatment</span><span class="headingEndMark"> — </span>The decision to treat an infected infant with antiviral therapy is based on the presence or absence of symptoms and on the immune status of the infant:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptomatic infection</strong> – We recommend antiviral treatment for infants with symptomatic congenital CMV infection (ie, infants with virologically confirmed congenital CMV and at least one end-organ symptom, including isolated central nervous system involvement [ie, the neurophenotype]) [<a href="#rid4">4,5</a>]. (See  <a class="medical medical_review" href="/d/html/14430.html" rel="external">"Congenital cytomegalovirus infection: Clinical features and diagnosis", section on 'Symptomatic neonate'</a>.)</p><p></p><p class="bulletIndent1">In infants with symptomatic congenital CMV infection, treatment with <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> and <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a> has been shown to improve long-term audiologic and neurodevelopmental outcomes [<a href="#rid1">1-3,6,7</a>]. A randomized clinical trial comparing six weeks of ganciclovir therapy with no treatment in 100 newborns with symptomatic congenital CMV infection with central nervous system involvement showed protection against development or progression of hearing loss [<a href="#rid1">1</a>]. A total of 43 patients in the study had audiologic assessment both at baseline and at one year or beyond; 5 of 24 treated infants had worsening of hearing compared with 13 of 19 control patients. In addition, antiviral treatment was associated with improved head circumference growth and neurodevelopmental milestones during the first 6 to 12 months of life [<a href="#rid1">1,2</a>]. A subsequent randomized clinical trial evaluated six months versus six weeks of valganciclovir therapy in 96 infants with symptomatic congenital CMV infection with and without central nervous system involvement. Children who received six months of antiviral therapy were more likely to have improved hearing or maintain normal hearing (odds ratio 2.61, 95% CI 1.05-6.43) and higher language and receptive communication scores at 24 months [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary immunodeficiency</strong> – Antiviral therapy is also provided to infants with congenital CMV infection who have an underlying primary immunodeficiency, regardless of the degree of symptoms. (See  <a class="medical medical_review" href="/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic infection with isolated hearing loss</strong> – For infants with isolated hearing loss, expert opinion varies as to whether the benefits of antiviral therapy outweigh the risks [<a href="#rid4">4,5,8,9</a>]. (See  <a class="medical medical_review" href="/d/html/14430.html" rel="external">"Congenital cytomegalovirus infection: Clinical features and diagnosis", section on 'Isolated hearing loss'</a>.)</p><p></p><p class="bulletIndent1">At the author's institution, decisions regarding treatment of such infants are individualized based on the values and preferences of the parents or caregivers. We may observe the infant, offer antiviral treatment with <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a>, or enroll in a clinical trial, if available.</p><p></p><p class="bulletIndent1">There are no published clinical trials of antiviral therapy in this specific population. A multicenter clinical trial addressing this issue was halted [<a href="#rid10">10</a>]. </p><p></p><p>We do <strong>not</strong> initiate antiviral therapy in asymptomatic infants with normal hearing since treatment has not been shown to improve audiologic outcomes for these patient [<a href="#rid11">11,12</a>]. At the author's institution, newborns identified to have congenital CMV infection who are asymptomatic with normal hearing are typically observed and followed carefully for signs of clinical disease or hearing loss. (See  <a class="medical medical_review" href="/d/html/14430.html" rel="external">"Congenital cytomegalovirus infection: Clinical features and diagnosis", section on 'Asymptomatic infection'</a>.)</p><p>In a small clinical trial involving 23 newborns with asymptomatic congenital CMV infection who were randomly assigned to three weeks of <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> therapy or no treatment, delayed-onset hearing loss occurred in none of the nine children in the ganciclovir group who were available for follow-up compared with two of nine in the untreated group; five children were lost to follow-up over the 10-year study period [<a href="#rid12">12</a>]. While the results from this study are promising, the small number of children treated precludes drawing firm conclusions as to whether therapy is truly beneficial. A subsequent randomized trial addressing this question was suspended due to safety concerns [<a href="#rid13">13</a>]. Further studies with larger numbers of asymptomatic infants are needed to clarify the benefits and risks of antiviral therapy in this group. </p><p class="headingAnchor" id="H92267959"><span class="h2">Timing</span><span class="headingEndMark"> — </span>Antiviral therapy should be initiated as soon as virologic testing is confirmed. Clinical trials investigating the effectiveness of antiviral therapy in congenital CMV disease have found a benefit when treatment is initiated within the first 30 days after birth. (See  <a class="medical medical_review" href="/d/html/14430.html" rel="external">"Congenital cytomegalovirus infection: Clinical features and diagnosis", section on 'Interpretation/diagnosis'</a> and <a class="local">'Who to treat'</a> above.)</p><p>Further studies are required to determine if starting antiviral therapy after one month of age is beneficial. A placebo-controlled trial evaluated <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a> in 35 infants and children (age one month to &lt;4 years) with delayed-onset CMV-related hearing loss [<a href="#rid14">14</a>]. The full results of the trial have not been published. Based on the available preliminary results, no patients in either treatment group had improvement in hearing at six-month follow-up.</p><p class="headingAnchor" id="H92267971"><span class="h2">Pretreatment evaluation</span><span class="headingEndMark"> — </span>Before starting antiviral treatment, the infected neonate should undergo a comprehensive evaluation [<a href="#rid4">4,5</a>]. At the author's institution, this includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Thorough physical examination to identify the full extent of CMV disease involvement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count, including differential and platelet count to establish baseline levels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver transaminases, and total and direct bilirubin to establish baseline levels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blood urea nitrogen (BUN) and creatinine to determine if dose adjustment of antiviral medications is warranted.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neuroimaging with ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI) to assess the degree of central nervous system involvement. Ultrasound is the preferred initial study for most infants, as discussed separately. (See  <a class="medical medical_review" href="/d/html/14430.html" rel="external">"Congenital cytomegalovirus infection: Clinical features and diagnosis", section on 'Post-diagnosis evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Audiologic testing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ophthalmologic examination.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMV viral load, measured with quantitative polymerase chain reaction (PCR) to establish baseline level of viremia.</p><p></p><p class="headingAnchor" id="H2090158"><span class="h2">Antiviral regimen</span><span class="headingEndMark"> — </span>The choice of initial antiviral agent (IV <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> versus oral <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a>) depends upon the severity of disease  (<a class="graphic graphic_table graphicRef100099" href="/d/graphic/100099.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef100748" href="/d/graphic/100748.html" rel="external">algorithm 1</a>):</p><p class="headingAnchor" id="H88091"><span class="h3">Life-threatening disease</span><span class="headingEndMark"> — </span>We generally use IV <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> initially for treatment of congenital CMV infection in infants with any of the following  (<a class="graphic graphic_algorithm graphicRef100750" href="/d/graphic/100750.html" rel="external">algorithm 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Viral sepsis-like syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Viral-induced hemophagocytic lymphohistiocytosis</p><p class="bulletIndent1"><span class="glyph">●</span>Pneumonitis</p><p class="bulletIndent1"><span class="glyph">●</span>Myocarditis</p><p class="bulletIndent1"><span class="glyph">●</span>Severe hepatitis</p><p class="bulletIndent1"><span class="glyph">●</span>Enterocolitis</p><p class="bulletIndent1"><span class="glyph">●</span>Severe and refractory thrombocytopenia</p><p class="bulletIndent1"><span class="glyph">●</span>Sight-threatening retinitis</p><p class="bulletIndent1"><span class="glyph">●</span>Severe neurologic disease</p><p class="bulletIndent1"><span class="glyph">●</span>Underlying primary immune disorder (eg, severe combined immunodeficiency [SCID]) regardless of degree of symptoms</p><p></p><p>We also use IV <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> in patients with gastrointestinal problems, which may interfere with absorption of enteral medications.</p><p>For infants with severe sight-threatening CMV-associated retinitis, systemic antiviral therapy may not be sufficient and intraocular antiviral therapy may be required. (See <a class="local">'Chorioretinitis'</a> below.)</p><p>Infants with primary immune disorders (eg, SCID) are at high risk of having severe manifestations and for developing resistant CMV strains. If the infant is being considered for bone marrow transplant in the immediate future, we may initially start two antivirals (<a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> and <a class="drug drug_pediatric" data-topicid="13325" href="/d/drug information/13325.html" rel="external">foscarnet</a>) to avoid the emergence of resistance. (See <a class="local">'Antiviral resistance'</a> below.)</p><p>Infants with the above conditions who lack life-threatening manifestations may be started on oral <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a> if they are well appearing or only mildly symptomatic, have a stable respiratory status (in room air or low supplemental oxygen), are tolerating oral feeds, and are gaining weight. (See <a class="local">'Non-life-threatening disease'</a> below.)</p><p>The dose of <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> is 6 mg/kg per dose administered IV every 12 hours [<a href="#rid1">1,2,4,15,16</a>]. The dose must be adjusted in neonates with renal failure. The dose should be increased with infant weight gain to maintain a dose of 6 mg/kg per dose. Adequate antiviral dosing is important to avoid resistance. Prolonged subtherapeutic dosing encourages the emergence of resistant strains. (See <a class="local">'Antiviral resistance'</a> below.)</p><p><a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">Ganciclovir</a> should be administered through a central venous catheter when possible. If brief ganciclovir treatment (&lt;2 weeks) is anticipated, a well-functioning peripheral IV may be used for administration, provided that the IV site is carefully monitored during ganciclovir infusion. (See <a class="local">'Adverse effects'</a> below.)</p><p>Infants may be transitioned to oral <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a> if clinically stable and able to take oral medications, usually after two to six weeks. We do not routinely recommend more than six weeks of IV <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a>, due to risks of toxicity with prolonged treatment. After transition to oral valganciclovir, therapy should continue for a total of six months in most cases [<a href="#rid5">5</a>].</p><p>More than six months of <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a> therapy may be given to infants with persistent viremia, persistent retinitis, severe central nervous system (CNS) involvement, and/or persistent liver disease and for infants with primary immune disorder. We suggest monitoring CMV viral load in severely symptomatic infants and prolonging antiviral treatment if viremia or end-organ disease has not resolved after six months. (See <a class="local">'Treatment response'</a> below.)</p><p>A case series of 23 infants treated with 12 months of <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a> found prolonged treatment was safe when monitored carefully, and it was associated with improved audiologic outcomes compared with historical controls who received six weeks of therapy [<a href="#rid16">16</a>].</p><p>If CMV viremia persists, and particularly if CMV viral load levels steadily or significantly increase on adequate antiviral therapy, emergence of antiviral resistance should be suspected. (See <a class="local">'Antiviral resistance'</a> below.)</p><p class="headingAnchor" id="H88098"><span class="h3">Non-life-threatening disease</span><span class="headingEndMark"> — </span>Non-life-threatening disease is defined more by the infant's general medical condition than by CMV-specific symptoms  (<a class="graphic graphic_table graphicRef100099" href="/d/graphic/100099.html" rel="external">table 1</a>). Infants with non-life-threatening disease are those that meet <strong>all</strong> of the following criteria:</p><p class="bulletIndent1"><span class="glyph">●</span>Well appearing or only mildly symptomatic, being managed in the newborn nursery or at home</p><p class="bulletIndent1"><span class="glyph">●</span>Stable respiratory status (in room air or low supplemental oxygen)</p><p class="bulletIndent1"><span class="glyph">●</span>Tolerating oral feeds</p><p class="bulletIndent1"><span class="glyph">●</span>Stable and gaining weight</p><p></p><p>These infants generally lack severe end-organ involvement. Examples of non-life-threatening disease include microcephaly or intracranial calcifications without seizures or encephalopathy, jaundice or hepatosplenomegaly without severe hepatitis or refractory thrombocytopenia, and isolated hearing loss.</p><p>Infants with non-life-threatening disease are treated with <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a> oral solution and monitored closely for clinical response  (<a class="graphic graphic_table graphicRef100099" href="/d/graphic/100099.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef100749" href="/d/graphic/100749.html" rel="external">algorithm 3</a>). (See <a class="local">'Treatment response'</a> below.)</p><p>The recommended dose of <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a> is 16 mg/kg per dose administered orally every 12 hours [<a href="#rid4">4</a>]. The dose must be adjusted in neonates with renal failure. The dose should be increased with infant weight gain to maintain a dose of 16 mg/kg per dose.</p><p class="bulletIndent1">In clinical studies, oral <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a> achieved plasma levels and clinical effectiveness similar to those of IV <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> [<a href="#rid17">17-21</a>]. Only valganciclovir clear oral solution from the manufacturer has been studied in patients with congenital CMV infections [<a href="#rid17">17</a>]. Pharmacy compounded suspensions should not be used.</p><p></p><p>We suggest six months of oral <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a> therapy in most cases of non-life-threatening infection.</p><p class="headingAnchor" id="H456742427"><span class="h2">Monitoring</span></p><p class="headingAnchor" id="H86566787"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>We initially obtain the following blood tests weekly in infants receiving <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> or <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a> therapy to monitor for signs of toxicity [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count with differential and platelet count – The complete blood count is monitored weekly for the first six weeks and if stable; it is subsequently monitored every two to four weeks throughout the treatment course.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver function tests (aspartate aminotransferase, alanine aminotransferase, total and direct bilirubin), monitored weekly initially and then monthly once stable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Kidney function tests (BUN and creatinine), monitored weekly initially and then every three months once stable.</p><p></p><p>Adverse effects associated with <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> and <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a> treatment include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neutropenia</strong> – Neutropenia occurs in 25 to 60 percent of neonates treated with IV <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> and approximately 15 to 20 percent of infants treated with oral <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a> [<a href="#rid1">1-3,22,23</a>]. It is rarely severe and usually resolves with holding the antiviral for one to seven days and reinstituting the same dose after the absolute neutrophil count (ANC) has recovered. Treatment discontinuation may be necessary if neutropenia recurs. Reinstituting one-half the antiviral dose may be helpful in select cases; however, we suggest not routinely using a lower dose of ganciclovir, because this encourages the emergence of ganciclovir resistance.</p><p></p><p class="bulletIndent1">Our approach to the management of ganciclovir-induced neutropenia is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the ANC falls below 500/microL we recheck the blood count the following day. If the ANC is below 500/microL on two consecutive days, we discontinue antiviral therapy and investigate for other causes of neutropenia (eg, concurrent viral infection or other medications). (See  <a class="medical medical_review" href="/d/html/8375.html" rel="external">"Overview of neutropenia in children and adolescents", section on 'Classification and etiology of isolated neutropenia'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Following discontinuation of therapy, the ANC is monitored two to three times per week and, once it has recovered to &gt;1000/microL, antiviral therapy is reinstituted at the previous dose.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the ANC does not recover promptly following discontinuation of therapy, administration of an alternative antiviral agent such as <a class="drug drug_pediatric" data-topicid="13325" href="/d/drug information/13325.html" rel="external">foscarnet</a> or <a class="drug drug_pediatric" data-topicid="13155" href="/d/drug information/13155.html" rel="external">cidofovir</a> may be warranted, particularly if the infant has severe, life-threatening symptoms of CMV infection. (See <a class="local">'Alternative antiviral agents'</a> below.)</p><p></p><p class="bulletIndent1">Alternative approaches to management of ganciclovir-induced neutropenia include dose adjustment and treatment with granulocyte colony-stimulating factor (G-CSF). We reserve the use of G-CSF for infants with severe CMV disease who are intolerant to the usual dosing regimens. We do not use it routinely. (See  <a class="medical medical_review" href="/d/html/8374.html" rel="external">"Drug-induced neutropenia and agranulocytosis", section on 'Granulocyte colony-stimulating factor'</a>.)</p><p></p><p class="bulletIndent1">In a clinical trial, neutropenia occurred in 29 of 46 infants treated with <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a>. Dose adjustment was required in 14 patients, two patients required treatment with granulocyte colony-stimulating factor and four patients required discontinuation of ganciclovir. The mean time (±standard deviation) of onset of neutropenia was 14.2 (±12.3) days [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1">Some infants with congenital CMV infection have a baseline neutropenia, with a relative lymphocytosis. In these cases, antiviral therapy may still be instituted and ANC observed closely.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombocytopenia</strong> – Thrombocytopenia (platelets &lt;50,000 cells/microL) has been reported to occur in 6 percent of infants during <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> therapy [<a href="#rid22">22,24</a>]. However, infants with congenital CMV infection often have low platelet counts at birth and the relative contribution of ganciclovir to the thrombocytopenia is unclear. In a randomized controlled trial, thrombocytopenia occurred at a similar rate in ganciclovir-treated and untreated infants (7 versus 5 percent, respectively) [<a href="#rid1">1</a>]. Worsening thrombocytopenia during antiviral therapy while CMV viral load is declining may suggest drug-induced thrombocytopenia or a splenic sequestration effect if the infant has significant splenomegaly. (See  <a class="medical medical_review" href="/d/html/4979.html" rel="external">"Neonatal thrombocytopenia: Etiology", section on 'Drug-related thrombocytopenia'</a> and  <a class="medical medical_review" href="/d/html/4979.html" rel="external">"Neonatal thrombocytopenia: Etiology", section on 'Sequestration and trapping'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatotoxicity</strong> – Hepatotoxicity has been observed in infants receiving <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a>, particularly at doses higher than 6 mg/kg [<a href="#rid22">22,24</a>]. Mild elevations in transaminases (&lt;100 int. units/L) are common, especially in infants receiving <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a>, because liver metabolism is required to cleave off the valine ester of the compound. Such mild elevations are generally not of concern.</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">Ganciclovir</a> or <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a> should be discontinued if transaminases rise to &gt;250 int. units/L with no alternative cause (eg, concurrent viral infection or other medications). (See  <a class="medical medical_review" href="/d/html/4958.html" rel="external">"Hepatitis viruses and the newborn: Clinical manifestations and treatment"</a>.)</p><p></p><p class="bulletIndent1">Transaminase levels should then be monitored weekly and when they decline, antiviral therapy can be restarted. If transaminase levels rise again, <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> should be stopped and infants with mild CMV disease can be monitored closely off antiviral therapy. Infants with severe or life-threatening infection may require treatment with an alternative antiviral agent. (See <a class="local">'Alternative antiviral agents'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nephrotoxicity</strong> – Elevated serum creatinine has been reported in &lt;1 percent of neonates treated with <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> and <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a> [<a href="#rid22">22,24</a>]. The dose of ganciclovir and valganciclovir should be adjusted in renal failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IV catheter events</strong> – Events related to the IV catheter during <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> treatment are common. Extravasation of the IV ganciclovir solution may produce local reaction, ulcers, and scarring. Therefore, we recommend ganciclovir be administered through a central venous catheter when possible. If brief ganciclovir treatment (&lt;2 weeks) is anticipated, a well-functioning peripheral IV may be used for administration, provided the IV site is carefully monitored during ganciclovir infusion. If signs of extravasation are observed, the infusion should be discontinued and other IV access sought. If ganciclovir therapy is anticipated for ≥2 weeks, we recommend placement of a peripherally inserted central catheter or other central venous access.</p><p></p><p class="bulletIndent1">Catheter-associated infection is a potential risk in infants receiving long-term IV <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> therapy, particularly in infants with primary immunodeficiency or ganciclovir-induced neutropenia. In a clinical trial, 7 percent (3 of 46) of treated infants developed catheter infections, and in some case reports up to 67 percent developed catheter infections [<a href="#rid1">1,7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term effects</strong> – There is no evidence that <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> or <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a> treatment in the newborn period leads to any significant long-term adverse effects despite evidence that these drugs may cause infertility in animal models [<a href="#rid24">24,25</a>].</p><p></p><p class="headingAnchor" id="H697096910"><span class="h3">Treatment response</span><span class="headingEndMark"> — </span>Treatment response can be assessed by monitoring clinical symptoms and level of viremia (ie, CMV viral load).</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical symptoms are monitored with:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Regular general physical examination, including growth parameters and head circumference</p><p class="bulletIndent2"><span class="glyph">•</span>Neurologic examination</p><p class="bulletIndent2"><span class="glyph">•</span>Hearing evaluation every three to six months</p><p class="bulletIndent2"><span class="glyph">•</span>Eye examination every three to six months; more frequent evaluations are required in infants with chorioretinitis (see <a class="local">'Chorioretinitis'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Viral load is measured with quantitative CMV DNA PCR in whole blood or plasma.</p><p></p><p class="bulletIndent1">Our practice is to measure viral load in all infants undergoing antiviral therapy for congenital CMV. The frequency of measurement depends on the severity of illness:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Life-threatening disease – We monitor CMV viral load weekly initially in infants with evidence of life-threatening end-organ disease and in infants with primary immunodeficiency (see <a class="local">'Life-threatening disease'</a> above). Once stable, viral load should be monitored every two to four weeks.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Non-life-threatening disease – We monitor viral load at the onset of treatment, at three months of age, and at six months of age in infants with non-life-threatening disease receiving oral <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a> in the outpatient setting. (See <a class="local">'Non-life-threatening disease'</a> above.)</p><p></p><p class="bulletIndent1">CMV viral load usually declines by the second to fourth week of <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> or <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a> therapy. In most cases, the goal of therapy is an undetectable or near undetectable viral load before stopping treatment. However, levels may not decline to undetectable in some patients. Clinical trial data have correlated low viral load with improved hearing outcomes if treatment is continued for six months [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1">Not all experts agree on routinely measuring CMV viral load, because its significance and value in determining duration of treatment and predicting outcomes have not been established.</p><p></p><p class="headingAnchor" id="H89639"><span class="h3">Treatment failure</span><span class="headingEndMark"> — </span>Evidence of treatment failure includes any of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Progressive end-organ disease despite adequate treatment</p><p class="bulletIndent1"><span class="glyph">●</span>Rising CMV viral load after two weeks of treatment (see <a class="local">'Treatment response'</a> above)</p><p class="bulletIndent1"><span class="glyph">●</span>Sustained significant increase in CMV viral load after an initial decline (see <a class="local">'Treatment response'</a> above)</p><p></p><p>Treatment failure may occur because of the host response (ie, immune dysfunction), emergence of a ganciclovir-resistant CMV strain, or a combination of both.</p><p>Infants at highest risk for treatment failure are those with primary immune deficiency (especially deficiency or dysfunction of T cells and natural killer cells) and those on immunosuppressive therapy such as glucocorticoids and chemotherapy. In some cases, refractory CMV disease may be the first indication of immunocompromise and additional testing for underlying immunodeficiency may be warranted. (See  <a class="medical medical_review" href="/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview"</a>.)</p><p class="headingAnchor" id="H89953"><span class="h2">Antiviral resistance</span><span class="headingEndMark"> — </span>Antiviral resistance is uncommon but has been documented in congenitally infected infants treated with <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> and <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a> [<a href="#rid26">26-32</a>]. Resistance should be suspected if CMV viral load rises significantly during therapy.</p><p>Resistant strains of CMV may compartmentalize and cause progressive disease within a single organ (eg, eye, brain, or lungs) [<a href="#rid33">33</a>]. Hence, antiviral resistance should also be suspected when there is progressive end-organ disease despite an appropriate decline in CMV viral load. Serial retinal examinations and/or measurement of viral titers in the affected organ (eg, cerebrospinal fluid or respiratory secretions) can be helpful in such cases.</p><p>Most ganciclovir-resistant CMV strains are susceptible to <a class="drug drug_pediatric" data-topicid="13325" href="/d/drug information/13325.html" rel="external">foscarnet</a> but may exhibit cross resistance to <a class="drug drug_pediatric" data-topicid="13155" href="/d/drug information/13155.html" rel="external">cidofovir</a> [<a href="#rid33">33</a>]. Strains simultaneously resistant to <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a>, cidofovir, and foscarnet rarely may occur. Adequate antiviral dosing is important to avoid resistance; subtherapeutic dosing encourages the emergence of resistant strains.</p><p>Management of suspected or documented antiviral resistance during treatment for congenital CMV disease depends on the severity of disease and the immune status of the infant. If the infant is otherwise stable and doing well, then cessation of antiviral therapy may be a safe option [<a href="#rid26">26</a>]. However, if the infant remains seriously ill or has a primary immune disorder, addition of another antiviral (eg, <a class="drug drug_pediatric" data-topicid="13325" href="/d/drug information/13325.html" rel="external">foscarnet</a>) may be indicated. Laboratory testing should be used to confirm antiviral resistance when it is clinically suspected; however, clinical antiviral resistance may be present even if a mutation is not detected on formal testing. If the clinical suspicion for antiviral resistance is high and the infant remains seriously ill, the antiviral regimen should be modified while awaiting test results. (See <a class="local">'Testing for antiviral resistance'</a> below and <a class="local">'Alternative antiviral agents'</a> below.)</p><p class="headingAnchor" id="H337450"><span class="h3">Testing for antiviral resistance</span><span class="headingEndMark"> — </span>Testing for antiviral resistance is accomplished using either genotypic or phenotypic assays [<a href="#rid32">32</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Genotypic assays detect viral gene sequence variations known to be associated with development of antiviral resistance. Genotypic assays are preferred because they are standardized, available in clinical reference laboratories, and yield results more rapidly than phenotypic assays.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Phenotypic assays directly measure drug susceptibilities of CMV viral isolates. Phenotypic assays are generally not used, because they are time-consuming and not standardized for clinical use.</p><p></p><p class="headingAnchor" id="H456742987"><span class="h3">Alternative antiviral agents</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="13325" href="/d/drug information/13325.html" rel="external">Foscarnet</a> and <a class="drug drug_pediatric" data-topicid="13155" href="/d/drug information/13155.html" rel="external">cidofovir</a> are not used routinely for treatment of congenital CMV infection, and data regarding their use in this setting are limited [<a href="#rid34">34-36</a>]. These agents may be used in select cases if there is suspected or confirmed ganciclovir-resistance or if significant toxicity is encountered during <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> or <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a> therapy. (See <a class="local">'Adverse effects'</a> above.)</p><p>The decision to use one of these alternative agents for treatment of congenital CMV infection also depends on the severity of illness. If the infant is otherwise stable and doing well, then cessation of antiviral therapy may be a safer option rather than transitioning to <a class="drug drug_pediatric" data-topicid="13325" href="/d/drug information/13325.html" rel="external">foscarnet</a> or <a class="drug drug_pediatric" data-topicid="13155" href="/d/drug information/13155.html" rel="external">cidofovir</a>. Consultation with a pediatric infectious disease expert is advised.</p><p>We have used combination <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> and <a class="drug drug_pediatric" data-topicid="13325" href="/d/drug information/13325.html" rel="external">foscarnet</a> treatment in CMV infected infants with an underlying deficiency or dysfunction of T cells or natural killer cells, especially if they fail to respond promptly to monotherapy with ganciclovir.</p><p><a class="drug drug_pediatric" data-topicid="13325" href="/d/drug information/13325.html" rel="external">Foscarnet</a> is preferred over <a class="drug drug_pediatric" data-topicid="13155" href="/d/drug information/13155.html" rel="external">cidofovir</a> in management of <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> resistance because cross resistance occurs less frequently. However, cidofovir may be used if genotypic testing reveals both ganciclovir and foscarnet resistance or if metabolic disturbances associated with foscarnet preclude its use.</p><p>Appropriate dosing and monitoring for these antivirals is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13325" href="/d/drug information/13325.html" rel="external">Foscarnet</a> – The recommended induction dose of foscarnet is 60 mg/kg per dose administered IV every eight hours for two to three weeks, followed by maintenance therapy at a dose of 90 mg/kg per dose once daily for two to three weeks.</p><p></p><p class="bulletIndent1">Toxicity associated with <a class="drug drug_pediatric" data-topicid="13325" href="/d/drug information/13325.html" rel="external">foscarnet</a> includes renal insufficiency and electrolyte derangements (particularly hypocalcemia or hypercalcemia, but also metabolic acidosis, hyper-/hypophosphatemia, hypokalemia, hypomagnesemia, and hyponatremia). Infants treated with foscarnet should have BUN, creatinine, and serum electrolytes (including sodium, potassium, calcium, magnesium, and phosphorus levels) monitored at least twice weekly. Providing adequate pre-dose hydration may minimize renal toxicity effects of foscarnet administration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13155" href="/d/drug information/13155.html" rel="external">Cidofovir</a> – The recommended dose of cidofovir is 5 mg/kg per dose administered IV every seven days for two weeks, then every other week for an additional four weeks. An alternative dosing regimen of 1 mg/kg per dose three times per week has also been used.</p><p></p><p class="bulletIndent1">To reduce renal and metabolic adverse effects, <a class="drug drug_pediatric" data-topicid="13155" href="/d/drug information/13155.html" rel="external">cidofovir</a> should be administered with <a class="drug drug_pediatric" data-topicid="12730" href="/d/drug information/12730.html" rel="external">probenecid</a> one hour before and eight hours after the dose of cidofovir. In addition, an IV fluid bolus should be given one hour before and one hour after the cidofovir infusion. The amount of fluid given will depend on the ability of the infant to tolerate the fluid bolus.</p><p></p><p class="bulletIndent1">Infants receiving <a class="drug drug_pediatric" data-topicid="13155" href="/d/drug information/13155.html" rel="external">cidofovir</a> should have blood tests to monitor for toxicities before each dose. In addition to renal and metabolic adverse effects, toxicity associated with cidofovir includes neutropenia and hepatotoxicity. Monitoring includes serum BUN, creatinine, calcium, magnesium, phosphorous, and uric acid levels; urine protein measurement; liver function tests; and complete blood count with differential. In addition, infants should have an ophthalmologic evaluation every one to two weeks while receiving cidofovir.</p><p></p><p>Other antivirals with activity against CMV (eg, <a class="drug drug_pediatric" data-topicid="131803" href="/d/drug information/131803.html" rel="external">brincidofovir</a>, <a class="drug drug_general" data-topicid="115632" href="/d/drug information/115632.html" rel="external">letermovir</a>, <a class="drug drug_pediatric" data-topicid="134464" href="/d/drug information/134464.html" rel="external">maribavir</a>) have not been studied in infants with congenital CMV infection and are not recommended outside of a clinical trial.</p><p class="headingAnchor" id="H90035"><span class="h2">Special circumstances</span></p><p class="headingAnchor" id="H90059"><span class="h3">Chorioretinitis</span><span class="headingEndMark"> — </span>In addition to treatment with IV <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> (see <a class="local">'Antiviral regimen'</a> above), infants with chorioretinitis require consultation with a pediatric ophthalmologist or retinal specialist. Monitoring of the retinal lesions every 7 to 10 days is recommended. If progression occurs, additional treatments may be indicated. For infants with severe sight-threatening CMV-associated chorioretinitis, systemic antivirals may not penetrate the eye in sufficient levels to adequately treat active CMV, and intravitreal antiviral therapy may be required. Intravitreal ganciclovir and <a class="drug drug_pediatric" data-topicid="13325" href="/d/drug information/13325.html" rel="external">foscarnet</a> have been used in such cases [<a href="#rid27">27,37</a>].</p><p class="headingAnchor" id="H90066"><span class="h3">Coinfection with other viruses</span><span class="headingEndMark"> — </span>On rare occasions, infants with congenital CMV have coinfections with other viruses. In our center, we have used <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> and/or <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a> to treat infants coinfected with both CMV and herpes simplex virus (HSV), with good results. Infants with congenital CMV disease who are coinfected with acyclovir-resistant HSV may be treated with <a class="drug drug_pediatric" data-topicid="13325" href="/d/drug information/13325.html" rel="external">foscarnet</a>. In infants coinfected with adenovirus, <a class="drug drug_pediatric" data-topicid="13155" href="/d/drug information/13155.html" rel="external">cidofovir</a> may be preferred over ganciclovir to provide cross coverage of both CMV and adenovirus. However, the CNS penetration of cidofovir is not well studied. (See <a class="local">'Alternative antiviral agents'</a> above.)</p><p class="headingAnchor" id="H22557962"><span class="h1">OUTCOME</span><span class="headingEndMark"> — </span>The outcome of congenital CMV infection depends upon the clinical pattern of disease at birth, as well as antiviral treatment provided in the newborn period.</p><p>In long-term follow-up studies, most of which were performed before treatment of symptomatic congenital CMV was routinely practiced, late sequelae included [<a href="#rid38">38-41</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Sensorineural hearing loss (SNHL; 50 to 58 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Intellectual disability (intelligence quotient &lt;70; 47 to 55 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Microcephaly (37 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Strabismus (25 to 30 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Dental disease (27 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Seizures (23 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Cortical visual impairment (14 to 22 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Chorioretinitis (20 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Cerebral palsy (13 to 27 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Death after the newborn period (2 to 6 percent)</p><p></p><p>In a longitudinal study of 178 infants with symptomatic congenital CMV infection followed for an average of 4.6 years, 72 percent were found to have at least one disability and 42 percent had multiple long-term sequelae [<a href="#rid39">39</a>].</p><p>In symptomatic infants, treatment with antiviral medications in early infancy appears to reduce sequelae, particularly hearing loss [<a href="#rid1">1-3,6,7</a>]. However, treated patients remain at risk for late progression of SNHL [<a href="#rid42">42</a>]. Therefore, long-term monitoring of hearing status is warranted for all patients with congenital CMV infection, regardless of whether treatment was provided. (See <a class="local">'Long-term follow-up'</a> below.)</p><p>Further longitudinal studies of treated infants are needed to fully understand the impact of antiviral treatment on long-term disability. </p><p>Infants with asymptomatic infection at birth are less likely to experience long-term disabilities, other than SNHL [<a href="#rid43">43,44</a>]. In a longitudinal study of 135 asymptomatic infants followed for 5 to 10 years, 14 percent developed long-term sequelae (7 percent had mild impairment, 4 percent had moderate impairment, and 3 percent had severe impairment) [<a href="#rid43">43</a>].</p><p>Poor long-term neurodevelopmental outcome is more likely in infants with microcephaly, chorioretinitis, and abnormal neuroimaging findings (particularly intracranial calcifications) in the newborn period. The absence of these factors predicts a normal or near-normal cognitive outcome for most infants [<a href="#rid45">45-47</a>]. The presence of petechiae and intrauterine growth restriction in the newborn are predictive of hearing loss [<a href="#rid48">48</a>]; however, hearing impairment is more likely in infants with central nervous system involvement compared with those who have transient neonatal findings or only a petechial rash [<a href="#rid49">49</a>].</p><p>Detection and quantitation of viremia may be helpful in predicting long-term outcomes, particularly hearing loss. A number of studies have identified an association between CMV viral load and hearing loss [<a href="#rid50">50-54</a>]. Low or no detectable virus in the blood during the neonatal period is associated with a low risk for hearing deficit later in life. However, this test has a poor positive predictive value for predicting hearing loss among asymptomatic newborns [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H86567155"><span class="h1">LONG-TERM FOLLOW-UP</span><span class="headingEndMark"> — </span>All children with congenital CMV infection (including those who are symptomatic at birth and those who are asymptomatic) should be followed throughout childhood and into adulthood for evidence of long-term effects of CMV.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hearing loss</strong> – The hearing loss in congenital CMV is progressive over the course of the lifetime. Hearing evaluations are recommended every three to six months during the first three years of life and annually thereafter until at least 18 years of age [<a href="#rid56">56-58</a>]. Hearing loss is usually detected by five years of age. If hearing loss is detected, assessments should continue into adulthood to monitor for hearing loss progression. Vestibular disorders are also common and can negatively impact postural and motor development [<a href="#rid59">59,60</a>].</p><p></p><p class="bulletIndent1">Children identified with hearing deficits may benefit from referral to early intervention programs and educational accommodations such as preferential classroom seating. Hearing aids may be needed, and, if progression to profound hearing loss occurs, cochlear implantation may be indicated. (See  <a class="medical medical_review" href="/d/html/6298.html" rel="external">"Hearing loss in children: Treatment"</a>.)</p><p></p><p class="bulletIndent1">In children with congenital CMV-related hearing loss, middle ear effusions can compound the problem, with associated changes in behavior or school performance. Clinicians should have a low threshold for referral to an otolaryngologist for evaluation and possible tympanostomy tube placement [<a href="#rid61">61</a>]. (See  <a class="medical medical_review" href="/d/html/87008.html" rel="external">"Otitis media with effusion (serous otitis media) in children: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central nervous system manifestations</strong> – Central nervous system manifestations (intellectual disability, cerebral palsy, and seizures) may require special education services and speech, language, occupational, and/or physical therapy [<a href="#rid57">57</a>]. Severely affected children with spasticity may require involvement of orthopedics and physical medicine consultations to determine the need for medicines to relieve spasticity, mobility aids, orthotics, or orthopedic procedures. (See  <a class="medical medical_review" href="/d/html/6191.html" rel="external">"Intellectual disability (ID) in children: Management, outcomes, and prevention"</a> and  <a class="medical medical_review" href="/d/html/6176.html" rel="external">"Cerebral palsy: Overview of management and prognosis"</a>.)</p><p></p><p class="bulletIndent1">Neurologic consultation may be indicated for seizure management. Rarely, seizures associated with polymicrogyria and other malformations of cortical development are refractory to medical management and require neurosurgical interventions. (See  <a class="medical medical_review" href="/d/html/6203.html" rel="external">"Seizures and epilepsy in children: Initial treatment and monitoring"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Behavioral and developmental disorders</strong> – Congenital CMV may also be associated with behavioral and developmental disorders, such as autism spectrum disorder, attention deficit, and hyperactivity, and these have been observed and diagnosed in children with congenital CMV, especially those with symptomatic infection [<a href="#rid62">62,63</a>]. However, when systematically studied or reviewed, the direct role of CMV in autism has not been convincingly established and requires further study [<a href="#rid63">63</a>]. All children with congenital CMV should undergo routine developmental screening to facilitate early recognition of these problems, as discussed separately. (See  <a class="medical medical_review" href="/d/html/6203.html" rel="external">"Seizures and epilepsy in children: Initial treatment and monitoring"</a> and  <a class="medical medical_review" href="/d/html/615.html" rel="external">"Developmental-behavioral surveillance and screening in primary care"</a> and  <a class="medical medical_review" href="/d/html/589.html" rel="external">"Autism spectrum disorder in children and adolescents: Surveillance and screening in primary care"</a> and  <a class="medical medical_review" href="/d/html/624.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eye disease</strong> – Chorioretinitis, retinopathy, optic atrophy, and strabismus require specialized management. Cortical visual impairment may also occur, especially in severely affected newborns with central nervous system involvement. Most ocular manifestations associated with congenital CMV are detectable at birth; however, later-onset retinitis can occur and may be severe and sight-threatening. Therefore, repeat ophthalmologic evaluations are recommended for newborns with symptomatic congenital CMV during the first year of life and then annually thereafter. Special therapies for the visually impaired or specialized cortical visual impairment therapies also may be helpful. (See  <a class="medical medical_review" href="/d/html/6261.html" rel="external">"Vision screening and assessment in infants and children"</a> and  <a class="medical medical_review" href="/d/html/6269.html" rel="external">"Evaluation and management of strabismus in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dental disease</strong> – Congenital CMV is associated with hypoplasia and hypocalcification of tooth enamel, affecting mainly primary dentition [<a href="#rid38">38,64</a>]. Affected teeth are susceptible to mechanical injury from minor trauma, and caries occurs frequently. Regular dental visits are an important component of the long-term care of these children. (See  <a class="medical medical_review" href="/d/html/6279.html" rel="external">"Preventive dental care and counseling for infants and young children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver disease</strong> – Chronic hepatitis resulting from congenital CMV disease is uncommon, and discerning which role, if any, CMV may be playing in chronic liver disease in a congenitally infected infant can be challenging. Abnormal liver function tests usually resolve during the first few weeks of life. Hepatomegaly usually resolves by three to six months. Infants with congenital CMV and persistent liver dysfunction or persistent direct hyperbilirubinemia should be evaluated for biliary atresia, alpha-1 antitrypsin deficiency, or other genetic or metabolic disorders since CMV and another diagnosis affecting liver function may coexist in the same infant and present a diagnostic challenge. (See  <a class="medical medical_review" href="/d/html/14369.html" rel="external">"Biliary atresia"</a> and  <a class="medical medical_review" href="/d/html/1429.html" rel="external">"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency", section on 'Hepatic disease'</a>.)</p><p></p><p class="headingAnchor" id="H22557968"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Prevention strategies are discussed separately and include:</p><p class="bulletIndent1"><span class="glyph">●</span>Personal protective measures (see  <a class="medical medical_review" href="/d/html/4810.html" rel="external">"Cytomegalovirus infection in pregnancy", section on 'Strategies for prevention of maternal and/or fetal infection'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antiviral therapy for pregnant individuals with primary CMV infection in early pregnancy (see  <a class="medical medical_review" href="/d/html/4810.html" rel="external">"Cytomegalovirus infection in pregnancy", section on 'Maternal treatment for fetal benefit'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vaccination (see  <a class="medical medical_review" href="/d/html/4810.html" rel="external">"Cytomegalovirus infection in pregnancy", section on 'Development of a vaccine'</a>)</p><p></p><p class="headingAnchor" id="H726718708"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111578.html" rel="external">"Society guideline links: TORCH infections"</a>.)</p><p class="headingAnchor" id="H90362"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance </strong>– Congenital cytomegalovirus (CMV) infection is the leading cause of nonhereditary sensorineural hearing loss (SNHL) and can cause other long-term neurodevelopmental disabilities. Infants congenitally infected with CMV may benefit from antiviral therapy, especially if treatment is initiated within the first month of life. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Categories of congenital CMV infection</strong> – Infants with congenital CMV infection are classified according to the presence or absence of apparent symptoms at birth (see <a class="local">'Terminology'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>"Symptomatic" refers to infants with one or more symptoms at birth. (See  <a class="medical medical_review" href="/d/html/14430.html" rel="external">"Congenital cytomegalovirus infection: Clinical features and diagnosis", section on 'Symptomatic neonate'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The "primary neurophenotype" is a subcategory of symptomatic infection referring to patients with only central nervous system manifestations. (See  <a class="medical medical_review" href="/d/html/14430.html" rel="external">"Congenital cytomegalovirus infection: Clinical features and diagnosis", section on 'Primary neurophenotype'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>"Asymptomatic" refers to infants with no apparent symptoms at birth.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>"Asymptomatic with isolated hearing loss" refers to infants with isolated hearing loss at birth but no other symptoms. These infants are not truly asymptomatic, but their disease is generally milder than that of symptomatic infants. (See <a class="local">'Terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Who to treat</strong> – For symptomatic newborns with virologically proven CMV infection, we recommend antiviral treatment rather than supportive care alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Treatment with <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> or <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a> has been shown to improve audiologic and neurodevelopmental outcomes in symptomatic newborns. (See <a class="local">'Who to treat'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiviral regimen</strong> – The choice of initial antiviral agent depends on the severity of the infection, clinical stability of the infant, and ability to tolerate oral medications (see <a class="local">'Antiviral regimen'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For infants with life-threatening disease, we suggest <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> as the initial antiviral agent  (<a class="graphic graphic_table graphicRef100099" href="/d/graphic/100099.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef100750" href="/d/graphic/100750.html" rel="external">algorithm 2</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The dose of ganciclovir is 6 mg/kg per dose administered intravenously (IV) every 12 hours. (See <a class="local">'Life-threatening disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For infants with non-life-threatening disease, we suggest <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a> as the antiviral agent  (<a class="graphic graphic_table graphicRef100099" href="/d/graphic/100099.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef100749" href="/d/graphic/100749.html" rel="external">algorithm 3</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The dose of valganciclovir is 16 mg/kg per dose administered orally every 12 hours. (See <a class="local">'Non-life-threatening disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13325" href="/d/drug information/13325.html" rel="external">Foscarnet</a> or <a class="drug drug_pediatric" data-topicid="13155" href="/d/drug information/13155.html" rel="external">cidofovir</a> are not routinely used for treatment of congenital CMV disease but may be indicated in special circumstances in high-risk infants. (See <a class="local">'Alternative antiviral agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of treatment</strong> – We provide a minimum of six months of antiviral therapy to all infants with symptomatic congenital CMV infection. Infants with life-threatening symptoms receive two to six weeks of IV <a class="drug drug_pediatric" data-topicid="13331" href="/d/drug information/13331.html" rel="external">ganciclovir</a> treatment initially and then transition to oral <a class="drug drug_pediatric" data-topicid="13002" href="/d/drug information/13002.html" rel="external">valganciclovir</a>, whereas infants with non-life-threatening symptoms receive oral valganciclovir for the entire six-month treatment course. We prolong treatment in severely affected infants with persistent retinitis, severe central nervous system involvement, persistent liver disease, persistent viremia, and/or underlying primary immune disorders. (See <a class="local">'Antiviral regimen'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Toxicity</strong> – The following blood tests are monitored weekly during the first few weeks of therapy and then be spaced out if stable includes (see <a class="local">'Adverse effects'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Complete blood count with differential and platelet count to detect drug-induced neutropenia and thrombocytopenia</p><p class="bulletIndent3"><span class="glyph">-</span>Liver function tests (aspartate aminotransferase, alanine aminotransferase, total and direct bilirubin) to detect drug-induced hepatitis</p><p class="bulletIndent3"><span class="glyph">-</span>Kidney function tests (blood urea nitrogen [BUN] and creatinine) to detect drug-induced nephrotoxicity and to determine if dose adjustment is necessary</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment response</strong> – Treatment response is assessed with clinical evaluation and measurement of viral load. Viral load usually declines by the second to fourth week of antiviral therapy. </p><p></p><p class="bulletIndent2">Antiviral resistance should be suspected in infants with progressive end-organ disease despite adequate treatment, rising viral load after two weeks of treatment, or a sustained increase in viral load after an initial decline. (See <a class="local">'Treatment failure'</a> above and <a class="local">'Antiviral resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcome </strong>– Potential long-term sequelae following congenital CMV infection include (see <a class="local">'Outcome'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>SNHL</p><p class="bulletIndent2"><span class="glyph">•</span>Intellectual disability</p><p class="bulletIndent2"><span class="glyph">•</span>Seizures</p><p class="bulletIndent2"><span class="glyph">•</span>Dental disease</p><p class="bulletIndent2"><span class="glyph">•</span>Vision impairment</p><p class="bulletIndent2"><span class="glyph">•</span>Cerebral palsy</p><p></p><p class="bulletIndent1">Sequelae are common in infants with symptomatic infection at birth. Infants who are asymptomatic at birth are at risk for late-onset SNHL, but other complications are uncommon. (See <a class="local">'Outcome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term follow-up</strong> – Children with congenital CMV should be followed throughout childhood and adolescence and into adulthood for evidence of long-term effects of CMV. (See <a class="local">'Long-term follow-up'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kimberlin DW, Lin CY, Sánchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003; 143:16.</a></li><li><a class="nounderline abstract_t">Oliver SE, Cloud GA, Sánchez PJ, et al. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. J Clin Virol 2009; 46 Suppl 4:S22.</a></li><li><a class="nounderline abstract_t">Kimberlin DW, Jester PM, Sánchez PJ, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med 2015; 372:933.</a></li><li class="breakAll">American Academy of Pediatrics. Cytomegalovirus infection. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds) (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.294.</li><li><a class="nounderline abstract_t">Luck SE, Wieringa JW, Blázquez-Gamero D, et al. Congenital Cytomegalovirus: A European Expert Consensus Statement on Diagnosis and Management. Pediatr Infect Dis J 2017; 36:1205.</a></li><li><a class="nounderline abstract_t">Royackers L, Rector E, Verhaert N, Desloovere C. Long-term audiological follow-up of children with congenital cytomegalovirus. B-ENT 2013; Suppl 21:57.</a></li><li><a class="nounderline abstract_t">Michaels MG, Greenberg DP, Sabo DL, Wald ER. Treatment of children with congenital cytomegalovirus infection with ganciclovir. Pediatr Infect Dis J 2003; 22:504.</a></li><li><a class="nounderline abstract_t">Schornagel FA, Oudesluys-Murphy AM, Vossen AC. Valganciclovir for Congenital Cytomegalovirus. N Engl J Med 2015; 372:2462.</a></li><li><a class="nounderline abstract_t">Lanzieri TM, Pesch MH, Grosse SD. Considering Antiviral Treatment to Preserve Hearing in Congenital CMV. Pediatrics 2023; 151.</a></li><li class="breakAll">Park A. Randomized controlled trial of Valfanciclovir for Asymptomatic Cytomegalovirus Infected Hearing Impaired Infants (ValEAR). Study record Detail. Available at: https://clinicaltrials.gov/ct2/show/NCT03107871 (Accessed on February 01, 2023).</li><li><a class="nounderline abstract_t">Duval M, Park AH. Congenital cytomegalovirus: what the otolaryngologist should know. Curr Opin Otolaryngol Head Neck Surg 2014; 22:495.</a></li><li><a class="nounderline abstract_t">Lackner A, Acham A, Alborno T, et al. Effect on hearing of ganciclovir therapy for asymptomatic congenital cytomegalovirus infection: four to 10 year follow up. J Laryngol Otol 2009; 123:391.</a></li><li class="breakAll">Asymptomatic congenital CMV treatment. Study record details. Available at: https://clinicaltrials.gov/ct2/show/study/NCT03301415 (Accessed on February 01, 2023).</li><li class="breakAll">National Institute of Allergy and Infectious Diseases. Valganciclovir therapy in infants and children with congenital CMV infection and hearing loss. Study record detail. Available at: https://clinicaltrials.gov/ct2/show/NCT01649869 (Accessed on March 31, 2023).</li><li><a class="nounderline abstract_t">Acosta EP, Brundage RC, King JR, et al. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clin Pharmacol Ther 2007; 81:867.</a></li><li><a class="nounderline abstract_t">Amir J, Wolf DG, Levy I. Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir. Eur J Pediatr 2010; 169:1061.</a></li><li><a class="nounderline abstract_t">Kimberlin DW, Acosta EP, Sánchez PJ, et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis 2008; 197:836.</a></li><li><a class="nounderline abstract_t">Galli L, Novelli A, Chiappini E, et al. Valganciclovir for congenital CMV infection: a pilot study on plasma concentration in newborns and infants. Pediatr Infect Dis J 2007; 26:451.</a></li><li><a class="nounderline abstract_t">Stronati M, Lombardi G, Garofoli F, et al. Pharmacokinetics, pharmacodynamics and clinical use of valganciclovir in newborns with symptomatic congenital cytomegalovirus infection. Curr Drug Metab 2013; 14:208.</a></li><li><a class="nounderline abstract_t">Lombardi G, Garofoli F, Villani P, et al. Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection. Eur J Clin Microbiol Infect Dis 2009; 28:1465.</a></li><li><a class="nounderline abstract_t">Irizarry K, Honigbaum S, Demmler-Harrison G, et al. Successful treatment with oral valganciclovir of primary CMV enterocolitis in a congenitally infected infant. Fetal Pediatr Pathol 2011; 30:437.</a></li><li><a class="nounderline abstract_t">Wang Y, Smith KP. Safety of alternative antiviral agents for neonatal herpes simplex virus encephalitis and disseminated infection. J Pediatr Pharmacol Ther 2014; 19:72.</a></li><li><a class="nounderline abstract_t">Leung J, Grosse SD, Yockey B, Lanzieri TM. Ganciclovir and Valganciclovir Use Among Infants With Congenital Cytomegalovirus: Data From a Multicenter Electronic Health Record Dataset in the United States. J Pediatric Infect Dis Soc 2022; 11:379.</a></li><li><a class="nounderline abstract_t">Gwee A, Curtis N, Connell TG, et al. Ganciclovir for the treatment of congenital cytomegalovirus: what are the side effects? Pediatr Infect Dis J 2014; 33:115.</a></li><li><a class="nounderline abstract_t">Faqi AS, Klug A, Merker HJ, Chahoud I. Ganciclovir induces reproductive hazards in male rats after short-term exposure. Hum Exp Toxicol 1997; 16:505.</a></li><li><a class="nounderline abstract_t">Morillo-Gutierrez B, Waugh S, Pickering A, et al. Emerging (val)ganciclovir resistance during treatment of congenital CMV infection: a case report and review of the literature. BMC Pediatr 2017; 17:181.</a></li><li><a class="nounderline abstract_t">Tawse KL, Baumal CR. Intravitreal foscarnet for recurring CMV retinitis in a congenitally infected premature infant. J AAPOS 2014; 18:78.</a></li><li><a class="nounderline abstract_t">Choi KY, Sharon B, Balfour HH Jr, et al. Emergence of antiviral resistance during oral valganciclovir treatment of an infant with congenital cytomegalovirus (CMV) infection. J Clin Virol 2013; 57:356.</a></li><li><a class="nounderline abstract_t">Garofoli F, Lombardi G, Angelini M, et al. Onset of valganciclovir resistance in two infants with congenital cytomegalovirus infection. Int J Infect Dis 2020; 98:150.</a></li><li><a class="nounderline abstract_t">Boss JD, Rosenberg K, Shah R. Dual Intravitreal Injections With Foscarnet and Ganciclovir for Ganciclovir-Resistant Recurrent Cytomegalovirus Retinitis in a Congenitally Infected Infant. J Pediatr Ophthalmol Strabismus 2016; 53:e58.</a></li><li><a class="nounderline abstract_t">Campanini G, Zavattoni M, Cristina E, et al. Multiple ganciclovir-resistant strains in a newborn with symptomatic congenital human cytomegalovirus infection. J Clin Virol 2012; 54:86.</a></li><li><a class="nounderline abstract_t">Torii Y, Horiba K, Kawada JI, et al. Detection of antiviral drug resistance in patients with congenital cytomegalovirus infection using long-read sequencing: a retrospective observational study. BMC Infect Dis 2022; 22:568.</a></li><li class="breakAll">Demmler-Harrison GJ. Cytomegalovirus. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.2022.</li><li><a class="nounderline abstract_t">Mareri A, Lasorella S, Iapadre G, et al. Anti-viral therapy for congenital cytomegalovirus infection: pharmacokinetics, efficacy and side effects. J Matern Fetal Neonatal Med 2016; 29:1657.</a></li><li><a class="nounderline abstract_t">Vora SB, Brothers AW, Waghmare A, Englund JA. Antiviral combination therapy for cytomegalovirus infection in high-risk infants. Antivir Ther 2018; 23:505.</a></li><li><a class="nounderline abstract_t">Rabinowicz S, Somech R, Yeshayahu Y. Foscarnet-related Hypercalcemia During CMV Treatment in an Infant With SCID: A Case Report and Review of Literature. J Pediatr Hematol Oncol 2017; 39:e173.</a></li><li><a class="nounderline abstract_t">Oschman A, Murthy V, Kollipara R, et al. Intravitreal ganciclovir for neonatal cytomegalovirus-associated retinitis: a case report. J Perinatol 2013; 33:329.</a></li><li class="breakAll">Britt W. Cytomegalovirus. In: Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant, 8th ed, Wilson CB, Nizet V, Maldonado YA, Remington JS, Klein JO (Eds), Elsevier Saunders, Philadelphia 2016. p.724.</li><li><a class="nounderline abstract_t">Dreher AM, Arora N, Fowler KB, et al. Spectrum of disease and outcome in children with symptomatic congenital cytomegalovirus infection. J Pediatr 2014; 164:855.</a></li><li><a class="nounderline abstract_t">Coats DK, Demmler GJ, Paysse EA, et al. Ophthalmologic findings in children with congenital cytomegalovirus infection. J AAPOS 2000; 4:110.</a></li><li><a class="nounderline abstract_t">Jin HD, Demmler-Harrison GJ, Coats DK, et al. Long-term Visual and Ocular Sequelae in Patients With Congenital Cytomegalovirus Infection. Pediatr Infect Dis J 2017; 36:877.</a></li><li><a class="nounderline abstract_t">Lanzieri TM, Caviness AC, Blum P, et al. Progressive, Long-Term Hearing Loss in Congenital CMV Disease After Ganciclovir Therapy. J Pediatric Infect Dis Soc 2022; 11:16.</a></li><li><a class="nounderline abstract_t">Townsend CL, Forsgren M, Ahlfors K, et al. Long-term outcomes of congenital cytomegalovirus infection in Sweden and the United Kingdom. Clin Infect Dis 2013; 56:1232.</a></li><li><a class="nounderline abstract_t">Korndewal MJ, Oudesluys-Murphy AM, Kroes ACM, et al. Long-term impairment attributable to congenital cytomegalovirus infection: a retrospective cohort study. Dev Med Child Neurol 2017; 59:1261.</a></li><li><a class="nounderline abstract_t">Boppana SB, Fowler KB, Vaid Y, et al. Neuroradiographic findings in the newborn period and long-term outcome in children with symptomatic congenital cytomegalovirus infection. Pediatrics 1997; 99:409.</a></li><li><a class="nounderline abstract_t">Noyola DE, Demmler GJ, Nelson CT, et al. Early predictors of neurodevelopmental outcome in symptomatic congenital cytomegalovirus infection. J Pediatr 2001; 138:325.</a></li><li><a class="nounderline abstract_t">Giannattasio A, Bruzzese D, Di Costanzo P, et al. Neuroimaging Profiles and Neurodevelopmental Outcome in Infants With Congenital Cytomegalovirus Infection. Pediatr Infect Dis J 2018; 37:1028.</a></li><li><a class="nounderline abstract_t">Rivera LB, Boppana SB, Fowler KB, et al. Predictors of hearing loss in children with symptomatic congenital cytomegalovirus infection. Pediatrics 2002; 110:762.</a></li><li><a class="nounderline abstract_t">Pinninti SG, Rodgers MD, Novak Z, et al. Clinical Predictors of Sensorineural Hearing Loss and Cognitive Outcome in Infants with Symptomatic Congenital Cytomegalovirus Infection. Pediatr Infect Dis J 2016; 35:924.</a></li><li><a class="nounderline abstract_t">Lanari M, Lazzarotto T, Venturi V, et al. Neonatal cytomegalovirus blood load and risk of sequelae in symptomatic and asymptomatic congenitally infected newborns. Pediatrics 2006; 117:e76.</a></li><li><a class="nounderline abstract_t">Ross SA, Novak Z, Fowler KB, et al. Cytomegalovirus blood viral load and hearing loss in young children with congenital infection. Pediatr Infect Dis J 2009; 28:588.</a></li><li><a class="nounderline abstract_t">Walter S, Atkinson C, Sharland M, et al. Congenital cytomegalovirus: association between dried blood spot viral load and hearing loss. Arch Dis Child Fetal Neonatal Ed 2008; 93:F280.</a></li><li><a class="nounderline abstract_t">Forner G, Abate D, Mengoli C, et al. High Cytomegalovirus (CMV) DNAemia Predicts CMV Sequelae in Asymptomatic Congenitally Infected Newborns Born to Women With Primary Infection During Pregnancy. J Infect Dis 2015; 212:67.</a></li><li><a class="nounderline abstract_t">Bradford RD, Cloud G, Lakeman AD, et al. Detection of cytomegalovirus (CMV) DNA by polymerase chain reaction is associated with hearing loss in newborns with symptomatic congenital CMV infection involving the central nervous system. J Infect Dis 2005; 191:227.</a></li><li><a class="nounderline abstract_t">Kawada J, Torii Y, Kawano Y, et al. Viral load in children with congenital cytomegalovirus infection identified on newborn hearing screening. J Clin Virol 2015; 65:41.</a></li><li><a class="nounderline abstract_t">Lanzieri TM, Chung W, Flores M, et al. Hearing Loss in Children With Asymptomatic Congenital Cytomegalovirus Infection. Pediatrics 2017; 139.</a></li><li><a class="nounderline abstract_t">Lanzieri TM, Leung J, Caviness AC, et al. Long-term outcomes of children with symptomatic congenital cytomegalovirus disease. J Perinatol 2017; 37:875.</a></li><li><a class="nounderline abstract_t">American Academy of Pediatrics, Joint Committee on Infant Hearing. Year 2007 position statement: Principles and guidelines for early hearing detection and intervention programs. Pediatrics 2007; 120:898.</a></li><li><a class="nounderline abstract_t">Bernard S, Wiener-Vacher S, Van Den Abbeele T, Teissier N. Vestibular Disorders in Children With Congenital Cytomegalovirus Infection. Pediatrics 2015; 136:e887.</a></li><li><a class="nounderline abstract_t">Pinninti S, Christy J, Almutairi A, et al. Vestibular, Gaze, and Balance Disorders in Asymptomatic Congenital Cytomegalovirus Infection. Pediatrics 2021; 147.</a></li><li><a class="nounderline abstract_t">Chung W, Leung J, Lanzieri TM, et al. Middle Ear Effusion in Children With Congenital Cytomegalovirus Infection. Pediatr Infect Dis J 2020; 39:273.</a></li><li><a class="nounderline abstract_t">Topham JD, Miller JA, Wright GW, et al. Inattention and Hyperactivity in Children with Symptomatic and Asymptomatic Congenital Cytomegalovirus. J Dev Behav Pediatr 2019; 40:743.</a></li><li><a class="nounderline abstract_t">Maeyama K, Tomioka K, Nagase H, et al. Congenital Cytomegalovirus Infection in Children with Autism Spectrum Disorder: Systematic Review and Meta-Analysis. J Autism Dev Disord 2018; 48:1483.</a></li><li><a class="nounderline abstract_t">Stagno S, Pass RF, Thomas JP, et al. Defects of tooth structure in congenital cytomegalovirus infection. Pediatrics 1982; 69:646.</a></li></ol></div><div id="topicVersionRevision">Topic 98188 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12915819" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19766534" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25738669" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Valganciclovir for symptomatic congenital cytomegalovirus disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25738669" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Valganciclovir for symptomatic congenital cytomegalovirus disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29140947" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Congenital Cytomegalovirus: A European Expert Consensus Statement on Diagnosis and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24383224" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Long-term audiological follow-up of children with congenital cytomegalovirus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12799506" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Treatment of children with congenital cytomegalovirus infection with ganciclovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26083217" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Valganciclovir for Congenital Cytomegalovirus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36695050" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Considering Antiviral Treatment to Preserve Hearing in Congenital CMV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36695050" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Considering Antiviral Treatment to Preserve Hearing in Congenital CMV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25222916" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Congenital cytomegalovirus: what the otolaryngologist should know.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18588736" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effect on hearing of ganciclovir therapy for asymptomatic congenital cytomegalovirus infection: four to 10 year follow up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18588736" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effect on hearing of ganciclovir therapy for asymptomatic congenital cytomegalovirus infection: four to 10 year follow up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18588736" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effect on hearing of ganciclovir therapy for asymptomatic congenital cytomegalovirus infection: four to 10 year follow up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17392728" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20232081" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18279073" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17468661" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Valganciclovir for congenital CMV infection: a pilot study on plasma concentration in newborns and infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22935067" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pharmacokinetics, pharmacodynamics and clinical use of valganciclovir in newborns with symptomatic congenital cytomegalovirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19763643" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21905765" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Successful treatment with oral valganciclovir of primary CMV enterocolitis in a congenitally infected infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25024666" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Safety of alternative antiviral agents for neonatal herpes simplex virus encephalitis and disseminated infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35532552" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Ganciclovir and Valganciclovir Use Among Infants With Congenital Cytomegalovirus: Data From a Multicenter Electronic Health Record Dataset in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24346602" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Ganciclovir for the treatment of congenital cytomegalovirus: what are the side effects?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9306137" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Ganciclovir induces reproductive hazards in male rats after short-term exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28830465" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Emerging (val)ganciclovir resistance during treatment of congenital CMV infection: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24568990" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Intravitreal foscarnet for recurring CMV retinitis in a congenitally infected premature infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23688863" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Emergence of antiviral resistance during oral valganciclovir treatment of an infant with congenital cytomegalovirus (CMV) infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32615325" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Onset of valganciclovir resistance in two infants with congenital cytomegalovirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27783090" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Dual Intravitreal Injections With Foscarnet and Ganciclovir for Ganciclovir-Resistant Recurrent Cytomegalovirus Retinitis in a Congenitally Infected Infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22381918" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Multiple ganciclovir-resistant strains in a newborn with symptomatic congenital human cytomegalovirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35733089" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Detection of antiviral drug resistance in patients with congenital cytomegalovirus infection using long-read sequencing: a retrospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35733089" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Detection of antiviral drug resistance in patients with congenital cytomegalovirus infection using long-read sequencing: a retrospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26135794" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Anti-viral therapy for congenital cytomegalovirus infection: pharmacokinetics, efficacy and side effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29790481" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Antiviral combination therapy for cytomegalovirus infection in high-risk infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27820135" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Foscarnet-related Hypercalcemia During CMV Treatment in an Infant With SCID: A Case Report and Review of Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23536045" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Intravitreal ganciclovir for neonatal cytomegalovirus-associated retinitis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23536045" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Intravitreal ganciclovir for neonatal cytomegalovirus-associated retinitis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24433826" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Spectrum of disease and outcome in children with symptomatic congenital cytomegalovirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10773810" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Ophthalmologic findings in children with congenital cytomegalovirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28399055" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Long-term Visual and Ocular Sequelae in Patients With Congenital Cytomegalovirus Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34718680" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Progressive, Long-Term Hearing Loss in Congenital CMV Disease After Ganciclovir Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23334811" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Long-term outcomes of congenital cytomegalovirus infection in Sweden and the United Kingdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28990181" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Long-term impairment attributable to congenital cytomegalovirus infection: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9041297" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Neuroradiographic findings in the newborn period and long-term outcome in children with symptomatic congenital cytomegalovirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11241037" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Early predictors of neurodevelopmental outcome in symptomatic congenital cytomegalovirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30222696" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Neuroimaging Profiles and Neurodevelopmental Outcome in Infants With Congenital Cytomegalovirus Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12359792" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Predictors of hearing loss in children with symptomatic congenital cytomegalovirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27195603" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clinical Predictors of Sensorineural Hearing Loss and Cognitive Outcome in Infants with Symptomatic Congenital Cytomegalovirus Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16326692" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Neonatal cytomegalovirus blood load and risk of sequelae in symptomatic and asymptomatic congenitally infected newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19478688" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Cytomegalovirus blood viral load and hearing loss in young children with congenital infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18039747" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Congenital cytomegalovirus: association between dried blood spot viral load and hearing loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25387583" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : High Cytomegalovirus (CMV) DNAemia Predicts CMV Sequelae in Asymptomatic Congenitally Infected Newborns Born to Women With Primary Infection During Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15609232" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Detection of cytomegalovirus (CMV) DNA by polymerase chain reaction is associated with hearing loss in newborns with symptomatic congenital CMV infection involving the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25766986" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Viral load in children with congenital cytomegalovirus infection identified on newborn hearing screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28209771" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Hearing Loss in Children With Asymptomatic Congenital Cytomegalovirus Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28383538" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Long-term outcomes of children with symptomatic congenital cytomegalovirus disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17908777" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Year 2007 position statement: Principles and guidelines for early hearing detection and intervention programs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26347442" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Vestibular Disorders in Children With Congenital Cytomegalovirus Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33419867" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Vestibular, Gaze, and Balance Disorders in Asymptomatic Congenital Cytomegalovirus Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31876611" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Middle Ear Effusion in Children With Congenital Cytomegalovirus Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31714416" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Inattention and Hyperactivity in Children with Symptomatic and Asymptomatic Congenital Cytomegalovirus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29185167" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Congenital Cytomegalovirus Infection in Children with Autism Spectrum Disorder: Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6281720" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Defects of tooth structure in congenital cytomegalovirus infection.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
